We here present and comprehensively characterize a novel GEMM of compound Apc/Kras/Trp53 mutated CRC (CCS1) that enables valid research of the biology and treatment response of the most common human CRC subtype. This evidence concerns the gene KRAS and colorectal carcinoma.